BTK and B-cell chronic lymphocytic leukemia: Efficacy assessments in 121 patients with CLL or small lymphocytic lymphoma (SLL), many of whom had previously received covalent BTK inhibitors (with a median of four prior lines of therapy), revealed an overall response rate (ORR) of 62%.